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Paper Poster Session 
Fungal diagnosis: from culture to molecular techniques 
Clinical characteristics, laboratory identification, and in vitro antifungal susceptibility 
of Trichomonascus (Candida) ciferrii isolates associated with granular myringitis
Jasper Chan*1, Chi-Ching Tsang1, Jin Yang2, Fanfan Xing2, Sally Leung3, Antonio Ngan3, 
Susanna K. P. Lau1, Patrick C. Y. Woo1, Kwok-Yung Yuen1
1The University of Hong Kong, State Key Laboratory of Emerging Infectious Diseases, Carol 
Yu Centre for Infection, Dept of Microbiology, Hong Kong, Hong Kong
2Department of Clinical Microbiology & Infection Control, Hku-Shenzhen Hospital, Shenzhen, 
China
3Department of Microbiology, Queen Mary Hospital, Hong Kong, Hong Kong
Background: Trichomonascus (Candida) ciferrii is an emerging opportunistic yeast pathogen that has 
been increasingly recognised in human infections. T. ciferrii has previously been implicated as the 
cause of tinea pedis, tinea cruris, onchychomycosis, and less commonly, fungaemia. Recently, we 
diagnosed four unusual cases of T. ciferrii-associated granular myringitis in Chinese patients in Hong 
Kong and Shenzhen, China. In this study, we report the clinical characteristics, laboratory 
identification, and in vitro antifungal susceptibility of T. ciferrii isolates associated with granular 
myringitis.
Material/methods: The case records of the patients with T. ciferrii-associated granular myringitis were 
reviewed. Their clinical characteristics and outcome were recorded into a predefined database. We 
compared the performance of Vitek 2 YST ID Card system, API 20C AUX, and MALDI-TOF MS for 
laboratory identification of the fungal isolates. We performed internal transcribed spacer (ITS) and 25S 
nrDNA gene sequencing for genotypic identification. Antifungal susceptibility testing was performed 
using the Sensititre YeastOne kit.
Results: A total of four patients with T. ciferrii-associated granular myringitis were seen at the Queen 
Mary Hospital and HKU-Shenzhen hospital between 1 January 2015 to 30 June 2015. There were 3 
males and 1 female. Their mean age was 38 years (range, 33-42 years). Three patients had no 
comorbidities and the remaining patient had nasopharyngeal carcinoma, diabetes mellitus, and 
hyperlipidemia. Their presenting symptoms included obstructive sensation and/or pruritis in their ears, 
pustular otorrhoea, and otalgia. They all responded to irrigation and topical antifungal (azole) cream. 
Swabs of the tymphanic membrane yielded fungal colonies on Sabouraud agar on day 3 of incubation 
at 37 oC. Although Vitex 2 YST ID Card system, API 20C AUX, and MALTI-TOF MS all reported the 
identification of “T. ciferrii”, none of them contained information on all three species of the T. ciferrii 
complex (namely, T. ciferrii, C. allociferrii, and C. mucifera) in their databases. Therefore, a more 
appropriate identification result should be “T. ciferrii complex”. ITS and 25S nrDNA gene sequencing 
accurately identified all the fungal isolates. All the isolates were susceptible to itraconazole, 
voriconazole, posaconazole, caspofungin, micafungin, and anidulafungin, but were resistant to 
fluconazole, amphotericin B, and flucytosine in vitro.
Conclusions: T. ciferrii may be associated with granular myringitis in patients with or without 
comorbidities. Vitek 2 YST ID Card system, API 20C AUX, and MALDI-TOF MS can identify T. ciferrii 
complex, but not speciation within the complex. Response to treatment with irrigation and topical 
antifungal cream are generally good. Antifungal susceptibility tests may aid in optimization of treatment 
choice.
